• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Analysis of reproducibility and robustness of OrganoPlate® 2-lane 96, a liver microphysiological system for studies of pharmacokinetics and toxicological assessment of drugs.分析 OrganoPlate® 2 道 96 孔板,一种用于研究药物药代动力学和毒理学评估的肝脏微生理系统的重现性和稳健性。
Toxicol In Vitro. 2022 Dec;85:105464. doi: 10.1016/j.tiv.2022.105464. Epub 2022 Aug 31.
2
A 3D microfluidic liver model for high throughput compound toxicity screening in the OrganoPlate®.一种用于 OrganoPlate®高通量化合物毒性筛选的 3D 微流控肝脏模型。
Toxicology. 2021 Feb 28;450:152667. doi: 10.1016/j.tox.2020.152667. Epub 2021 Jan 6.
3
Characterizing the reproducibility in using a liver microphysiological system for assaying drug toxicity, metabolism, and accumulation.描述使用肝微生理系统测定药物毒性、代谢和积累的可重复性。
Clin Transl Sci. 2021 May;14(3):1049-1061. doi: 10.1111/cts.12969. Epub 2021 Apr 3.
4
Reproducibility and Robustness of a Liver Microphysiological System PhysioMimix LC12 under Varying Culture Conditions and Cell Type Combinations.肝脏微生理系统PhysioMimix LC12在不同培养条件和细胞类型组合下的可重复性和稳健性
Bioengineering (Basel). 2023 Oct 14;10(10):1195. doi: 10.3390/bioengineering10101195.
5
Analysis of reproducibility and robustness of a renal proximal tubule microphysiological system OrganoPlate 3-lane 40 for in vitro studies of drug transport and toxicity.分析用于药物转运和毒性体外研究的肾近端小管微生理系统 OrganoPlate 3 道 40 的可重复性和稳健性。
Toxicol Sci. 2023 Oct 30;196(1):52-70. doi: 10.1093/toxsci/kfad080.
6
Chemically induced hepatotoxicity in human stem cell-induced hepatocytes compared with primary hepatocytes and HepG2.化学诱导的人诱导多能干细胞源性肝细胞与原代肝细胞和 HepG2 细胞的肝毒性比较。
Cell Biol Toxicol. 2016 Oct;32(5):403-17. doi: 10.1007/s10565-016-9342-0. Epub 2016 Jun 11.
7
3-D culture and endothelial cells improve maturity of human pluripotent stem cell-derived hepatocytes.三维培养和内皮细胞提高人多能干细胞来源肝细胞的成熟度。
Acta Biomater. 2019 Sep 1;95:371-381. doi: 10.1016/j.actbio.2019.07.047. Epub 2019 Jul 27.
8
Modulation of human iPSC-derived hepatocyte phenotype via extracellular matrix microarrays.通过细胞外基质微阵列对人诱导多能干细胞源性肝细胞表型的调控。
Acta Biomater. 2022 Nov;153:216-230. doi: 10.1016/j.actbio.2022.09.013. Epub 2022 Sep 14.
9
3D hepatic cultures simultaneously maintain primary hepatocyte and liver sinusoidal endothelial cell phenotypes.3D 肝培养物同时维持原代肝细胞和肝窦内皮细胞表型。
PLoS One. 2010 Nov 12;5(11):e15456. doi: 10.1371/journal.pone.0015456.
10
Characterization of rat or human hepatocytes cultured in microphysiological systems (MPS) to identify hepatotoxicity.在微生理系统(MPS)中培养大鼠或人肝细胞以鉴定肝毒性的特征。
Toxicol In Vitro. 2017 Apr;40:170-183. doi: 10.1016/j.tiv.2017.01.007. Epub 2017 Jan 13.

引用本文的文献

1
Microfluidic Systems to Mimic the Blood-Brain Barrier: from Market to Engineering Challenges and Perspectives.用于模拟血脑屏障的微流控系统:从市场到工程挑战与展望
ACS Biomater Sci Eng. 2025 Jun 25. doi: 10.1021/acsbiomaterials.4c02221.
2
Liver-on-chips for drug discovery and development.用于药物发现与开发的芯片肝脏模型
Mater Today Bio. 2024 Jul 2;27:101143. doi: 10.1016/j.mtbio.2024.101143. eCollection 2024 Aug.
3
Physiological platelet aggregation assay to mitigate drug-induced thrombocytopenia using a microphysiological system.使用微生理系统进行生理血小板聚集测定以减轻药物诱导的血小板减少症。
Sci Rep. 2024 Jun 19;14(1):14109. doi: 10.1038/s41598-024-64063-y.
4
Hazard and risk characterization of 56 structurally diverse PFAS using a targeted battery of broad coverage assays using six human cell types.使用涵盖六种人类细胞类型的靶向广谱测定法对 56 种结构多样的全氟和多氟烷基物质进行危害和风险特征描述。
Toxicology. 2024 Mar;503:153763. doi: 10.1016/j.tox.2024.153763. Epub 2024 Feb 27.
5
Reproducibility and Robustness of a Liver Microphysiological System PhysioMimix LC12 under Varying Culture Conditions and Cell Type Combinations.肝脏微生理系统PhysioMimix LC12在不同培养条件和细胞类型组合下的可重复性和稳健性
Bioengineering (Basel). 2023 Oct 14;10(10):1195. doi: 10.3390/bioengineering10101195.
6
Analysis of reproducibility and robustness of a renal proximal tubule microphysiological system OrganoPlate 3-lane 40 for in vitro studies of drug transport and toxicity.分析用于药物转运和毒性体外研究的肾近端小管微生理系统 OrganoPlate 3 道 40 的可重复性和稳健性。
Toxicol Sci. 2023 Oct 30;196(1):52-70. doi: 10.1093/toxsci/kfad080.
7
Human induced pluripotent stem cell-derived liver-on-a-chip for studying drug metabolism: the challenge of the cytochrome P450 family.用于研究药物代谢的人诱导多能干细胞衍生的芯片肝:细胞色素P450家族的挑战。
Front Pharmacol. 2023 Jun 28;14:1223108. doi: 10.3389/fphar.2023.1223108. eCollection 2023.
8
Reanalysis of Trichloroethylene and Tetrachloroethylene Metabolism to Glutathione Conjugates Using Human, Rat, and Mouse Liver Models to Improve Precision in Risk Characterization.使用人、大鼠和小鼠肝模型重新分析三氯乙烯和四氯乙烯代谢为谷胱甘肽缀合物,以提高风险特征描述的准确性。
Environ Health Perspect. 2022 Nov;130(11):117009. doi: 10.1289/EHP12006. Epub 2022 Nov 29.
9
Evaluation of Metabolism of a Defined Pesticide Mixture through Multiple In Vitro Liver Models.通过多种体外肝脏模型评估特定农药混合物的代谢情况。
Toxics. 2022 Sep 27;10(10):566. doi: 10.3390/toxics10100566.

本文引用的文献

1
Microphysiological Systems Evaluation: Experience of TEX-VAL Tissue Chip Testing Consortium.微生理系统评估:TEX-VAL 组织芯片测试联盟的经验。
Toxicol Sci. 2022 Jul 28;188(2):143-152. doi: 10.1093/toxsci/kfac061.
2
Prediction of hepatic drug clearance with a human microfluidic four-cell liver acinus microphysiology system.应用人微流控四细胞肝小叶微生理系统预测肝脏药物清除率。
Toxicology. 2021 Nov;463:152954. doi: 10.1016/j.tox.2021.152954. Epub 2021 Sep 17.
3
Key Characteristics of Human Hepatotoxicants as a Basis for Identification and Characterization of the Causes of Liver Toxicity.人用肝毒物的关键特征作为鉴定和描述肝毒性原因的基础。
Hepatology. 2021 Dec;74(6):3486-3496. doi: 10.1002/hep.31999. Epub 2021 Jul 13.
4
Opportunities and challenges with microphysiological systems: a pharma end-user perspective.微生理系统面临的机遇与挑战:制药终端用户视角
Nat Rev Drug Discov. 2021 May;20(5):327-328. doi: 10.1038/d41573-020-00030-2.
5
Characterizing the reproducibility in using a liver microphysiological system for assaying drug toxicity, metabolism, and accumulation.描述使用肝微生理系统测定药物毒性、代谢和积累的可重复性。
Clin Transl Sci. 2021 May;14(3):1049-1061. doi: 10.1111/cts.12969. Epub 2021 Apr 3.
6
A 3D microfluidic liver model for high throughput compound toxicity screening in the OrganoPlate®.一种用于 OrganoPlate®高通量化合物毒性筛选的 3D 微流控肝脏模型。
Toxicology. 2021 Feb 28;450:152667. doi: 10.1016/j.tox.2020.152667. Epub 2021 Jan 6.
7
Analysis of reproducibility and robustness of a human microfluidic four-cell liver acinus microphysiology system (LAMPS).分析人类微流控四细胞肝小叶微生理系统 (LAMPS) 的重现性和稳健性。
Toxicology. 2021 Jan 30;448:152651. doi: 10.1016/j.tox.2020.152651. Epub 2020 Dec 8.
8
Organs-on-chips: into the next decade.芯片器官:迈向新的十年。
Nat Rev Drug Discov. 2021 May;20(5):345-361. doi: 10.1038/s41573-020-0079-3. Epub 2020 Sep 10.
9
Differential Monocyte Actuation in a Three-Organ Functional Innate Immune System-on-a-Chip.三器官功能性芯片上固有免疫系统中的单核细胞差异激活
Adv Sci (Weinh). 2020 Jun 2;7(13):2000323. doi: 10.1002/advs.202000323. eCollection 2020 Jul.
10
Development and Application of a Transcriptomic Signature of Bioactivation in an Advanced In Vitro Liver Model to Reduce Drug-induced Liver Injury Risk Early in the Pharmaceutical Pipeline.在药物研发早期,利用先进的体外肝模型构建生物活化转录组特征以降低药物性肝损伤风险的方法学建立与应用
Toxicol Sci. 2020 Sep 1;177(1):121-139. doi: 10.1093/toxsci/kfaa094.

分析 OrganoPlate® 2 道 96 孔板,一种用于研究药物药代动力学和毒理学评估的肝脏微生理系统的重现性和稳健性。

Analysis of reproducibility and robustness of OrganoPlate® 2-lane 96, a liver microphysiological system for studies of pharmacokinetics and toxicological assessment of drugs.

机构信息

Department of Veterinary Physiology and Pharmacology, Texas A&M University, College Station, TX 77843, USA; Laboratory for Drug Discovery and Development, Shionogi Pharmaceutical Research Center, Shionogi & Co., Ltd., Osaka 561-0825, Japan.

Department of Veterinary Physiology and Pharmacology, Texas A&M University, College Station, TX 77843, USA.

出版信息

Toxicol In Vitro. 2022 Dec;85:105464. doi: 10.1016/j.tiv.2022.105464. Epub 2022 Aug 31.

DOI:10.1016/j.tiv.2022.105464
PMID:36057418
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10015056/
Abstract

Establishing the functionality, reproducibility, robustness, and reliability of microphysiological systems is a critical need for adoption of these technologies. A high throughput microphysiological system for liver studies was recently proposed in which induced pluripotent stem cell-derived hepatocytes (iHeps) and non-parenchymal cells (endothelial cells and THP-1 cells differentiated with phorbol 12-myristate 13-acetate into macrophage-like cells) were co-cultured in OrganoPlate® 2-lane 96 devices. The goal of this study was to evaluate this platform using additional cell types and conditions and characterize its utility and reproducibility. Primary human hepatocytes or iHeps, with and without non-parenchymal cells, were cultured for up to 17 days. Image-based cell viability, albumin and urea secretion into culture media, CYP3A4 activity and drug metabolism were assessed. The iHeps co-cultured with non-parenchymal cells demonstrated stable cell viability and function up to 17 days; however, variability was appreciable both within and among studies. The iHeps in monoculture did not form clusters and lost viability and function over time. The primary human hepatocytes in monoculture also exhibited low cell viability and hepatic function. Metabolism of various drugs was most efficient when iHeps were co-cultured with non-parenchymal cells. Overall, we found that the OrganoPlate® 2-lane 96 device, when used with iHeps and non-parenchymal cells, is a functional liver microphysiological model; however, the high-throughput nature of this model is somewhat dampened by the need for replicates to compensate for high variability.

摘要

建立微生理系统的功能、可重复性、稳健性和可靠性对于这些技术的采用是至关重要的。最近提出了一种用于肝脏研究的高通量微生理系统,其中诱导多能干细胞衍生的肝细胞(iHeps)和非实质细胞(内皮细胞和用佛波醇 12-肉豆蔻酸 13-乙酸酯分化为巨噬细胞样细胞的 THP-1 细胞)在 OrganoPlate®2 道 96 孔设备中进行共培养。本研究的目的是使用其他细胞类型和条件评估该平台,并表征其实用性和可重复性。原代人肝细胞或 iHeps,有或没有非实质细胞,培养长达 17 天。评估基于图像的细胞活力、白蛋白和尿素分泌到培养基中、CYP3A4 活性和药物代谢。与非实质细胞共培养的 iHeps 表现出稳定的细胞活力和功能,长达 17 天;然而,在研究内部和之间都存在明显的可变性。在单核培养中的 iHeps 不会形成簇,并且随着时间的推移会失去活力和功能。单核培养中的原代人肝细胞也表现出低的细胞活力和肝脏功能。当 iHeps 与非实质细胞共培养时,各种药物的代谢效率最高。总的来说,我们发现 OrganoPlate®2 道 96 孔设备,当与 iHeps 和非实质细胞一起使用时,是一个功能性的肝微生理模型;然而,由于需要重复以补偿高变异性,该模型的高通量性质在一定程度上受到了影响。